Search

401. Access to Medicare Part D plans: a comparison of metropolitan and nonmetropolitan areas

Author(s):

Nataliansyah, Mochamad, author
Salako, Abiodun, author
Ullrich, Fred, author
Mueller, Keith, author

Publication:

Iowa City, IA : Rural Policy Research Institute, May 2020

Subject(s):

Medicare Part D -- statistics & numerical data
Rural Population
Urban Population
United States

402. County-level 14-day COVID-19 case trajectories

Author(s):

Ullrich, Fred, author
Mueller, Keith, author

Publication:

Iowa City, IA : Rural Policy Research Institute, May 21, 2020

Subject(s):

Coronavirus Infections -- epidemiology
Pandemics
United States

403. Telepharmacy rules and statutes: a 3-year update for all 50 states

Author(s):

Semprini, Jason, author
Ullrich, Fred, author
Mueller, Keith J., author

Publication:

Iowa City, IA : Rural Policy Research Institute, July 2020

Subject(s):

Legislation, Pharmacy
Telemedicine -- legislation & jurisprudence
Rural Population
United States

404. The market mechanism and health insurance in rural places: lessons learned from an economics and policy perspective

Author(s):

Barker, Abigail, author
McBride, Timothy D., author
Mueller, Keith J., author
Huntzberry, Kelsey A., author

Publication:

Iowa City, IA : Rural Policy Research Institute, February 2019

Subject(s):

Health Insurance Exchanges
Insurance, Health
Rural Population
United States

405. Assessing user fees under the Biosimilar User Fee Amendments of 2017

Publication:

Silver Spring, MD : Center for Drug Evaluation and Research, January 2020

Subject(s):

Biosimilar Pharmaceuticals -- economics
Drug Development -- economics
United States
United States. Department of Health and Human Services
United States. Food and Drug Administration

406. Testing of retroviral vector-based human gene therapy products for replication competent retrovirus during product manufacture and patient follow-up

Publication:

Silver Spring, MD : Center for Biologics Evaluation and Research, January 2020

Subject(s):

Drug Contamination
Genetic Therapy
Genetic Vectors
Retroviridae
Virus Replication
United States
United States. Department of Health and Human Services
United States. Food and Drug Administration

407. In vitro drug interaction studies: cytochrome P-450 enzyme- and transporter-mediated drug interactions

Publication:

Silver Spring, MD : Center for Drug Evaluation and Research, January 2020

Subject(s):

Drug Interactions
Cytochrome P-450 Enzyme System
In Vitro Techniques
Membrane Transport Proteins
United States
United States. Department of Health and Human Services
United States. Food and Drug Administration

408. Registered apprenticeships: a viable career path for the early childhood workforce

Publication:

Washington, D.C. : Bipartisan Policy Center, September 2019

Subject(s):

Child Care
Credentialing
Inservice Training
Workforce
United States

409. Hospitalizations for newborns with neonatal abstinence syndrome: 2018

Publication:

Harrisburg, PA : Pennsylvania Health Care Cost Containment Council, June 2019

Subject(s):

Hospitalization -- statistics & numerical data
Neonatal Abstinence Syndrome
Pennsylvania
United States

410. Hospitalizations for opioid overdose: three-year review

Publication:

Harrisburg, PA : Pennsylvania Health Care Cost Containment Council, September 2019

Subject(s):

Drug Overdose -- epidemiology
Hospitalization -- statistics & numerical data
Opioid-Related Disorders
Pennsylvania
United States

411. Examining two approaches to U.S. drug pricing: international prices and therapeutic equivalency

Publication:

Washington, D.C. : Bipartisan Policy Center, October 2019

Subject(s):

Costs and Cost Analysis
Drug Costs
Insurance, Health, Reimbursement
Therapeutic Equivalency
Europe
United States

412. Loosening COVID-19 social distancing interventions: lessons learned from abroad

Publication:

Washington, D.C. : Bipartisan Policy Center, April 2020

Subject(s):

Coronavirus Infections -- epidemiology
Disease Transmission, Infectious -- prevention & control
International Health Regulations
Physical Distancing
Pandemics -- prevention & control
United States

413. Paid family leave in the United States: a primer on working family trends and paid family leave

Publication:

Washington, D.C. : Bipartisan Policy Center, February 2020

Subject(s):

Family Leave -- statistics & numerical data
Family Leave -- trends
Employment -- trends
United States

414. Confronting rural America’s health care crisis: BPC Rural Health Task Force policy recommendations

Publication:

Washington, D.C. : Bipartisan Policy Center, April 2020

Subject(s):

Health Services Accessibility
Rural Health Services
Health Policy
Hospitals, Rural
United States

415. Human gene therapy for retinal disorders

Publication:

Silver Spring, MD : Center for Biologics Evaluation and Research, January 2020

Subject(s):

Clinical Trials as Topic
Genetic Therapy
Drug Evaluation, Preclinical
Retinal Diseases -- therapy
Investigational New Drug Application
United States
United States. Department of Health and Human Services
United States. Food and Drug Administration

416. Clinical drug interaction studies: cytochrome P450 enzyme- and transporter-mediated drug interactions

Publication:

Silver Spring, MD : Center for Drug Evaluation and Research, January 2020

Subject(s):

Drug Interactions
Clinical Trials as Topic
Cytochrome P-450 Enzyme System
Drugs, Investigational
Membrane Transport Proteins
United States
United States. Department of Health and Human Services
United States. Food and Drug Administration

417. Human gene therapy for rare diseases

Publication:

Silver Spring, MD : Center for Biologics Evaluation and Research, January 2020

Subject(s):

Drug Development
Genetic Therapy
Rare Diseases -- therapy
Clinical Trials as Topic
Drug Evaluation, Preclinical
United States
United States. Department of Health and Human Services
United States. Food and Drug Administration

418. Cancer hospitalizations for Pennsylvania children

Publication:

Harrisburg, PA : Pennsylvania Health Care Cost Containment Council, September 2019

Subject(s):

Hospitalization -- statistics & numerical data
Neoplasms
Adolescent
Child
Pennsylvania
United States

419. Ending HIV in America: policy and program insights from local health agencies and providers

Publication:

Washington, D.C. : Bipartisan Policy Center, September 2019

Subject(s):

HIV Infections -- epidemiology
HIV Infections -- prevention & control
Community Health Services
Health Policy
Health Services Accessibility
United States

420. Policy options for integrating care for individuals with both Medicare and Medicaid

Publication:

Washington, DC : Bipartisan Policy Center, April 2020

Subject(s):

Delivery of Health Care, Integrated
Dual MEDICAID MEDICARE Eligibility
United States

421. Hospital performance report: 31 common medical procedures and treatments : Central & Northeastern Pennsylvania : FFY 2008

Publication:

Harrisburg, PA : Pennsylvania Health Care Cost Containment Council, [2009]

Subject(s):

Diagnosis-Related Groups -- statistics & numerical data
Hospital Costs -- statistics & numerical data
Hospitals -- statistics & numerical data
Outcome Assessment, Health Care -- statistics & numerical data
Quality Indicators, Health Care
Pennsylvania
United States

422. Medicare: the basics

Publication:

Washington, DC : George Washington University, January 4, 2016

Subject(s):

Medicare -- organization & administration
United States

423. Competitive generic therapies

Publication:

Silver Spring, MD : Center for Drug Evaluation and Research, March 2020

Subject(s):

Drug Approval
Drugs, Generic
Investigational New Drug Application
United States
United States. Department of Health and Human Services
United States. Food and Drug Administration

424. Biological product deviation reporting for blood and plasma establishments

Publication:

Silver Spring, MD : Center for Biologics Evaluation and Research, March 2020

Subject(s):

Biological Products
Blood Banks -- standards
Mandatory Reporting
United States
United States. Department of Health and Human Services
United States. Food and Drug Administration

425. Center for Devices and Radiological Health (CDRH) appeals processes: questions and answers about 517A : guidance for industry and Food and Drug Administration staff

Publication:

Silver Spring, MD : Center for Devices and Radiological Health, March 27, 2020

Subject(s):

Device Approval
United States
United States. Department of Health and Human Services
United States. Food and Drug Administration
United States.

426. Enforcement policy for sterilizers, disinfectant devices, and air purifiers during the coronavirus disease 2019 (COVID-19) public health emergency: guidance for industry and Food and Drug Administration staff

Publication:

[Silver Spring, MD] : Center for Devices and Radiological Health, March 2020

Subject(s):

Air Filters
Coronavirus Infections -- epidemiology
Disinfection -- instrumentation
Pandemics
Sterilization -- instrumentation
United States
United States. Department of Health and Human Services
United States. Food and Drug Administration

427. Enforcement policy for gowns, other apparel, and gloves during the coronavirus disease (COVID-19) public health emergency: guidance for industry and Food and Drug Administration staff

Publication:

Silver Spring, MD : Center for Devices and Radiological Health, March 2020

Subject(s):

Coronavirus Infections -- epidemiology
Pandemics
Personal Protective Equipment -- supply & distribution
Surgical Attire -- supply & distribution
United States
United States. Department of Health and Human Services
United States. Food and Drug Administration

428. Enforcement policy for ventilators and accessories and other respiratory devices during the coronavirus disease 2019 (COVID-19) public health emergency: guidance for industry and Food and Drug Administration staff

Publication:

Silver Spring, MD : Center for Center for Devices and Radiological Health, March 2020

Subject(s):

Coronavirus Infections -- epidemiology
Pandemics
Ventilators, Mechanical -- supply & distribution
United States
United States. Department of Health and Human Services
United States. Food and Drug Administration

429. Maximizing data interoperability and integration to support value-based care

Author(s):

Ozanich, Gary, author
Ramos, Christal, author

Publication:

[Washington, D.C.] : Department of Health and Human Services, Office of the Assistant Secretary for Planning and Evaluation, 2020

Subject(s):

Electronic Health Records
Health Information Interoperability
Value-Based Purchasing
United States

430. Understanding substance use disorder (SUD) treatment needs using assessment data: final report

Author(s):

Richardson, John, author
Cowell, Alex, author
Villeneuve, Eric, author
Hinde, Jesse, author
Olmstead, Kristine Rae, author
Karon, Sarita, author

Publication:

[Washington, D.C.] : United States Department of Health and Human Services, Office of the Assistant Secretary for Planning and Evaluation, October 2020

Subject(s):

Needs Assessment
Substance-Related Disorders -- therapy
Patient Acuity
State Government
United States

431. Understanding the characteristics of older adults in different residential settings: data sources and trends

Author(s):

Toth, Matthew, author
Palmer, Lauren A. Martin, author
Bercaw, Lawren E., author
Johnson, Ruby, author
Jones, Jessica, author
Love, Rebekah, author
Voltmer, Helena, author
Karon, Sarita, author

Publication:

[Washington, D.C.] : United States Department of Health and Human Services, Office of the Assistant Secretary for Planning and Evaluation, Behavioral Health, Disability and Aging Policy, October 2020

Subject(s):

Residence Characteristics -- statistics & numerical data
Aged
Long-Term Care
United States

432. Advance care planning among Medicare fee-for-service beneficiaries and practitioners: final report

Author(s):

He, Fang, author
Gasdaska, Angela, author
Friedman, Hannah, author
Wedehas, Brendan, author
Kirk, Alexis, author
Broyles, Ila, author
Karon, Sarita L., author

Publication:

[Washington, D.C.] : United States Department of Health and Human Services, Office of the Assistant Secretary for Planning and Evaluation, September 2020

Subject(s):

Advance Care Planning
Medicare
Fee-for-Service Plans
United States

433. Understanding substance use coercion as a barrier to economic stability for survivors of intimate partner violence: policy implications

Publication:

[Washington, D.C.] : United States Department of Health and Human Services, Office of the Assistant Secretary for Planning and Evaluation and Youth Services Bureau, Division of Family Violence Prevention and Services, October 2020

Subject(s):

Coercion
Domestic Violence
Substance-Related Disorders
United States

434. Projections of poverty and program eligibility during the COVID-19 pandemic

Author(s):

Macartney, Suzanne, author
Ghertner, Robin, author
Giannarelli, Linda, author
Wheaton, Laura, author
Morton, Joyce, author
Shantz, Kathryn, author

Publication:

[Washington, D.C.] : United States Department of Health and Human Services, Office of the Assistant Secretary for Planning and Evaluation, October 2020

Subject(s):

COVID-19 -- economics
Poverty -- trends
United States

435. COVID-19 intensifies nursing home workforce challenges

Author(s):

Denny-Brown, Noelle, author
Stone, Denise, author
Hays, Burke, author
Gallagher, Dayna, author

Publication:

[Washington, D.C.] : United States Department of Health and Human Services, Office of the Assistant Secretary for Planning and Evaluation, Office of Behavioral Health, Disability, and Aging Policy October 2020

Subject(s):

COVID-19
Health Workforce
Nursing Homes
Pandemics
United States

436. Healthcare and health insurance choices: how consumers decide

Publication:

[New York, New York] : FAIR Health, Inc., 2016

Subject(s):

Consumer Behavior
Delivery of Health Care
Insurance, Health
United States

437. Changes in home health care use in Medicare Advantage compared to traditional Medicare: 2011--2016

Author(s):

Zuckerman, Stephen, author
Skopec, Laura, author
Aarons, Joshua, author
Berenson, Robert A., author
Feder, Judith, author
Wissoker, Douglas, author
Huckfeldt, Peter J., author

Publication:

[Washington, D.C.] : United States Department of Health and Human Services, Office of the Assistant Secretary for Planning and Evaluation, Office of Behavioral Health, Disability, and Aging Policy, September 2020

Subject(s):

Facilities and Services Utilization
Home Care Services
Medicare
Medicare Part C
United States

438. Answers to questions for the record following a hearing conducted by the House Committee on the Budget: key design components and considerations for establishing a single-payer health care system

Publication:

[Washington, DC] : Congressional Budget Office, December 20, 2019

Subject(s):

Single-Payer System -- organization & administration
Budgets
United States

439. Safety and performance based pathway: guidance for industry and Food and Drug Administration

Publication:

Silver Spring, MD : Center for Biologics Evaluation and Research, September 20, 2019

Subject(s):

Drug Approval
Therapeutic Equivalency
United States
United States. Department of Health and Human Services
United States. Food and Drug Administration

440. Opioid use disorder: developing depot buprenorphine products for treatment

Publication:

Silver Spring, MD : Center for Drug Evaluation and Research, February 2019

Subject(s):

Buprenorphine -- therapeutic use
Drug Development
Opioid-Related Disorders -- drug therapy
United States
United States. Department of Health and Human Services
United States. Food and Drug Administration

441. The least burdensome provisions: concept and principles : guidance for industry and Food and Drug Administration staff

Publication:

Silver Spring, MD : Center for Biologics Evaluation and Research, February 5, 2019

Subject(s):

Device Approval
United States
United States. Department of Health and Human Services
United States. Food and Drug Administration

442. Enrichment strategies for clinical trials to support determination of effectiveness of human drugs and biological products

Publication:

Silver Spring, MD : Center for Drug Evaluation and Research, March 2019

Subject(s):

Clinical Trials as Topic
Prognosis
Research Design
United States
United States. Department of Health and Human Services
United States. Food and Drug Administration

443. Standards development and the use of standards in regulatory submissions reviewed in the Center for Biologics Evaluation and Research

Publication:

Silver Spring, MD : Center for Biologics Evaluation and Research, March 2019

Subject(s):

Guidelines as Topic
United States
United States. Department of Health and Human Services
United States. Food and Drug Administration
Center for Biologics Evaluation and Research (U.S.)

444. Interpretation of and compliance policy for certain label requirement: applicability of certain Federal Food, Drug, and Cosmetic Act requirements to vape shops

Publication:

Silver Spring, MD : Food and Drug Administration, Center for Tobacco Products, March 2019

Subject(s):

Electronic Nicotine Delivery Systems -- standards
Product Labeling -- legislation & jurisprudence
Tobacco Products -- legislation & jurisprudence
United States
United States. Department of Health and Human Services
United States. Food and Drug Administration
United States.

445. Pediatric information incorporated into human prescription drug and biological product labeling

Publication:

Silver Spring, MD : Center for Drug Evaluation and Research, March 2019

Subject(s):

Drug Labeling -- standards
Pediatrics
Product Labeling -- standards
United States
United States. Department of Health and Human Services
United States. Food and Drug Administration

446. Recommended content and format of non-clinical bench performance testing information in premarket submissions: guidance for industry and Food and Drug Administration staff

Publication:

Silver Spring, MD : Center for Devices and Radiological Health, December 20, 2019

Subject(s):

Device Approval -- standards
Materials Testing -- standards
United States
United States. Department of Health and Human Services
United States. Food and Drug Administration

447. Hematologic malignancies: regulatory considerations for use of minimal residual disease in development of drug and biological products for treatment

Publication:

Silver Spring, MD : Center for Drug Evaluation and Research, January 2020

Subject(s):

Biomarkers
Clinical Trials as Topic
Drug Approval
Drug Development
Drugs, Investigational
Hematologic Neoplasms -- drug therapy
Investigational New Drug Application
Neoplasm, Residual
United States
United States. Department of Health and Human Services
United States. Food and Drug Administration

448. Unique device identification: convenience kits : guidance for industry and Food and Drug Administration staff

Publication:

Silver Spring, MD : Center for Devices and Radiological Health, April 26, 2019

Subject(s):

Equipment and Supplies -- standards
Product Labeling -- standards
United States
United States. Department of Health and Human Services
United States. Food and Drug Administration

449. 30-Day notices, 135-day premarket approval (PMA) supplements and 75-day humanitarian device exemption (HDE) supplements for manufacturing method or process changes: guidance for industry and Food and Drug Administration staff

Publication:

Silver Spring, MD : Center for Devices and Radiological Health, December 16, 2019

Subject(s):

Device Approval -- standards
Equipment and Supplies -- standards
Manufactured Materials -- standards
United States
United States. Department of Health and Human Services
United States. Food and Drug Administration
United States.

450. Classification and requirements for laser illuminated projectors (LIPs): (Laser Notice No. 57) : guidance for industry and Food and Drug Administration staff

Publication:

Silver Spring, MD : Center for Devices and Radiological Health, May 8, 2019

Subject(s):

Equipment Safety
Lasers -- classification
Lasers -- standards
United States
United States. Department of Health and Human Services
United States. Food and Drug Administration